Prolia (denosumab) / Amgen, BeOne Medicines, Daiichi Sankyo - LARVOL DELTA

Denosumab therapy beyond 10 years: subsequent treatment and densitometric outcomes. (PubMed, Endocr Pract) - "After ≥20 doses of denosumab, most patients continued treatment, guided largely by the 20th-dose BMD T-score. Continuing denosumab beyond 10 years resulted in further increases in BMD at the lumbar spine and maintenance of BMD at the femoral neck, whereas transition to zoledronic acid led to partial loss of previous gains and transition to romosozumab increased lumbar spine BMD only."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Early detection of medication-related osteonecrosis of the jaw (MRONJ) in patients with metastatic breast cancer using FDG-PET/CT scans. (PubMed, EClinicalMedicine) - "This cohort study in Austria included all patients with metastatic breast cancer who were receiving denosumab and regular PET/CTs, diagnosed with MRONJ between 2000 and 2022 at the Department of Obstetrics and Gynecology Innsbruck...Given that the majority of patients receive regular PET/CTs, our results provide an excellent opportunity for early intervention when MRONJ is detected with a considerable lead time. This study received no external funding."

Journal • Breast Cancer • Gynecology • Infectious Disease • Musculoskeletal Pain • Obstetrics • Oncology • Pain • Solid Tumor

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of anti-sclerostin antibodies compared to placebo, alendronate, teriparatide and denosumab in the treatment of osteoporosis...The study results demonstrate that anti-sclerostin antibodies can be used to treat postmenopausal osteoporosis. https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251103597."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Osteoporosis • Rheumatology

Giant Cell Tumor of Bone: Initial Results of Anti-Sclerostin Therapy (AAOS 2026) - "Anti-sclerostin therapy with blosozumab reduced GCTB cell growth in vitro, while denosumab increased it, suggesting differential effects on neoplastic stromal cells and potential therapeutic value."

Giant Cell Tumor of Bone • Oncology • Osteosarcoma • Solid Tumor

Concurrent administration of teriparatide and denosumab: attenuation of bone accrual? Editorial on "Comparative Bone Histomorphometry Effects of Combined Denosumab and Teriparatide versus Monotherapy in Postmenopausal Women with Osteoporosis: A Randomized Controlled Trial". (PubMed, J Bone Miner Res) - No abstract available

Journal • Monotherapy • Osteoporosis • Rheumatology

Intraoperative MRI for giant cell tumor of bone after denosumab and other selected tumors: A pilot study. (PubMed, Acta Radiol Open) - "No iMRI-related complications occurred. iMRI is a feasible and safe adjunct in bone tumor surgery, enhancing detection of residual tumor and supporting joint-preserving procedures, particularly in GCTB after denosumab."

Journal • Giant Cell Tumor of Bone • Musculoskeletal Diseases • Oncology • Orthopedics • Osteosarcoma • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Renal Sarcoidosis Presenting as Acute Kidney Injury With Persistent Hypercalcemia in the Absence of Respiratory Symptoms: A Report of a Rare Case. (PubMed, Cureus) - "This report underscores the significance of maintaining a broad differential diagnosis in cases of unexplained AKI and hypercalcemia, especially in the absence of respiratory symptoms. Early recognition of key imaging and biochemical clues allows prompt initiation of therapy and helps optimize patient outcomes."

Journal • Acute Kidney Injury • Anorexia • Endocrine Disorders • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Sarcoidosis

Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice. (PubMed, PLoS One) - "Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes."

Journal • Endocrine Disorders • Fatigue • Gastroenterology • Gastrointestinal Disorder • Giant Cell Tumor of Bone • Infectious Disease • Musculoskeletal Diseases • Oncology • Orthopedics • Osteosarcoma • Sarcoma • Solid Tumor

Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management. (PubMed, Kidney Med) - "This comprehensive review illustrates the mechanisms of MAH, discusses relevant investigations, and focuses on management strategies tailored to the severity of hypercalcemia in patients with cancer. Additionally, we address the dose adjustments for antihypercalcemic agents in patients with reduced glomerular filtration rate and explore potential areas for developing targeted therapies to better address MAH."

Journal • Review • CNS Disorders • Endocrine Disorders • Metabolic Disorders • Nephrology • Oncology • Renal Disease

Real-world outcomes of denosumab treatment in patients undergoing hemodialysis for osteoporosis: A 3-year observational study. (PubMed, Clin Nephrol) - "These findings highlight the potential of denosumab in managing osteoporosis in patients undergoing hemodialysis but also underscore the need for careful monitoring of calcium levels to mitigate adverse effects. Therefore, adequate calcium replacement is required to prevent severe hypocalcemia. This study provides valuable real-world evidence to guide therapeutic strategies for improving bone health in patients with ESKD."

Journal • Observational data • Real-world evidence • Chronic Kidney Disease • Endocrine Disorders • Nephrology • Osteoporosis • Renal Disease • Rheumatology

Superior Efficacy of Denosumab over Zoledronic Acid in Increasing Femoral Neck Bone Mineral Density in Osteoporosis Patients with Type 2 Diabetes Mellitus. (PubMed, Endocr Pract) - "The results suggest that DEN should be considered as a potentially better option for T2DM patients who have low femoral neck BMD."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. (PubMed, Lancet Diabetes Endocrinol) - P4 | "In postmenopausal women at high risk of fracture, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip BMD. Given the expense, injection burden, and potential adverse effects of romosozumab, this abbreviated approach could broaden access to this uniquely effective therapy."

Head-to-Head • Journal • Back Pain • Cardiovascular • Cough • Dermatology • Fatigue • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Respiratory Diseases • Rheumatology

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. (PubMed, JAMA Netw Open) - "Observed treatment effects on overall survival (OS) differed substantially in the first 2 randomized clinical trials of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer...VISION randomized participants to receive treatment with or without Lu-177 PSMA in addition to physicians' choice of protocol-permitted treatments (PPT; approved hormonal treatments [such as abiraterone and enzalutamide], bisphosphonates, radiotherapy, denosumab, or glucocorticoids), excluding cabazitaxel...Findings of this secondary analysis of the TheraP and VISION randomized clinical trials suggest that the choice of comparator treatments (ie, cabazitaxel vs PPT) may explain the difference in the observed effect of Lu-177 PSMA on OS between the 2 trials. Causal inference methods such as RPSFTM and IPCW may help rule out crossover as a plausible explanation."

Clinical • Journal • Metastases • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (PubMed, Ann Oncol) - "PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis."

Journal • Cardiovascular • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Hematological Disorders • Hypertension • Musculoskeletal Diseases • Neutropenia • Oncology • Pain • Prostate Cancer • Solid Tumor

A prospective, multicenter, observational study evaluating the efficacy and safety of denosumab (Luxan®) in preventing knee prosthesis displacement in postmenopausal patients with osteoporosis after total knee arthroplasty (ChiCTR) - P4 | N=250 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Chongqing Medical University; No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

New P4 trial • Orthopedics • Osteoporosis • Pain • Rheumatology

Glucolipid-Cardiometabolic-Osteo Effects of Denosumab on Male Osteoporosis: A Randomized Open-Label Controlled Trial (GOODMAN) (ChiCTR) - P4 | N=600 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P4 trial • Osteoporosis • Rheumatology

The efficacy of denosumab vs zoledronic acid in surgical/non-surgical treatment of patients with osteoporotic thoracolumbar fractures: a prospective, multicenter, randomized, double-blind, controlled study (ChiCTR) - P=N/A | N=188 | Recruiting | Sponsor: Hebei Medical University Third Hospital; Hebei Medical University Third Hospital

New trial • Musculoskeletal Diseases • Orthopedics

Denosumab improves periprosthetic bone mineral density and bone strength after primary total hip arthroplasty by regulating the expression of bone type I collagen (ChiCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New trial • Immunology • Orthopedics • Osteoarthritis • Osteoporosis • Pain • Rheumatology

Comparison of the Efficacy of Teriparatide Injection Combined with Denosumab Injection Versus Denosumab Injection Alone in Patients with Osteoporosis (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Department of Endocrinology and Metabolism, West China Hospital, Sichuan University; West China Hospital, SCU

New trial • Orthopedics • Osteoporosis • Rheumatology

The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide. (PubMed, J Bone Miner Metab) - "In subjects who received 1/W-TPTD and 2/W-TPTD for about 1 year followed by sequential administration of BP or denosumab, significant improvements in BMD were continuously observed. Furthermore, significant improvements in cortical sBMD and vBMD were also demonstrated by analysis using 3D-SHAPER. Both 1/W-TPTD and 2/W-TPTD were effective in the treatment of osteoporosis by using anti-resorptive agents for sequential administration."

Journal • Osteoporosis • Rheumatology

Enhancing Oral Health Literacy to Prevent Medication-Related Osteonecrosis of the Jaw: Awareness and Compliance Among Breast Cancer Patients Receiving Bone-Modifying Agents. (PubMed, J Cancer Educ) - No abstract available

Compliance • Journal • Breast Cancer • Oncology • Solid Tumor

ZM-306416 prevents ovariectomy-induced bone loss by promoting osteoblastogenesis and inhibiting osteoclastogenesis. (PubMed, J Orthop Surg Res) - "Our study revealed that ZM has a dual anti-osteoporosis effect by promoting osteoblastogenesis and inhibiting osteoclastogenesis, which is mediated by activation of the Wnt/β-catenin signaling pathway and suppression of the NF-κB/MAPK cascades. These findings suggest that ZM could be a promising therapeutic agent for alleviating osteoporosis."

Journal • Atopic Dermatitis • Dermatology • Immunology • Osteoporosis • Rheumatology • TRAP

Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort. (PubMed, Osteoporos Int) - "Hypocalcemia following denosumab is common in real-world practice, particularly in patients on diuretics or with low vitamin D levels. Clinicians should consider comprehensive pre-treatment risk assessment and tailored monitoring strategies to mitigate adverse outcomes in osteoporosis management."

Journal • Endocrine Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology

Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report. (PubMed, Cureus) - "He received capmatinib (800 mg/day) and denosumab, with SBRT to vertebral metastases and later to the primary lung tumor. Temporary suspension of capmatinib during SBRT, along with careful monitoring, optimized tolerability, and outcomes. This case supports the feasibility and potential synergy of precision multimodal therapy in MET-driven oligometastatic NSCLC, highlighting the need for further prospective studies."

IO biomarker • Journal • Diabetes • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus • MET • NKX2-1 • PD-L1

Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Insights from the global REASSURE study (ESMO 2025) - P, P3 | "Incidence of fractures was slightly higher in ALL pts (10%) with fewer pts receiving concomitant BPAs (denosumab 28% and zoledronic acid 13%)...Table: 2401P ENZ/RAD (N=45) ALL Pts (N=1,472) Median time since initial diagnosis of bone metastases to study entry, months 14 23 Median time since castration resistant cancer to study entry, months 7 13 Extent of disease, % Bone only metastases 80 81 Bone metastases + lymph node only 9 13 Disease burden, % 20 metastases but not Superscan 18 20 Superscan 4 6 Laboratory values, median ALP (U/L) 131 133 PSA (ng/mL) 33 59 Prior abiraterone, % 40 48 Prior docetaxel, % 16 39 Prior Sipuleucel-T, % 18 9 Conclusions In this subgroup of pts treated with combined ENZ/RAD in a real-world setting, there was no new safety signal...Pts received ENZ/RAD earlier in the disease course based on time from mCRPC, time from initial diagnosis of bone metastases and prior docetaxel. Fracture incidence was low in ENZ/RAD, and the majority of pts..."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor